Anti-siglec-7 antibodies and methods of use thereof
AssigneeAlector LLC
InventorsKate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Claims31
An isolated monoclonal anti-Siglec-7 antibody, wherein the anti-Siglec-7 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 18 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 18, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 31 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 31, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 44 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 44, and the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 57 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 57, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 70 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 70, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 83 or an amino acid sequence with at least about 90% homology to SEQ ID NO:
- 83.
An isolated monoclonal anti-Siglec 7 antibody, wherein the anti-Siglec-7 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 18 or the amino acid sequence of SEQ ID NO:
- 18 having one conservative amino acid substitution, an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 31 or the amino acid sequence of SEQ ID NO:
- 31 having one conservative amino acid substitution, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 44 or the amino acid sequence of SEQ ID NO:
- 44 having one conservative amino acid substitution, and wherein the heavy chain variable domain comprises an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 57 or the amino acid sequence of SEQ ID NO:
- 57 having one conservative amino acid substitution, an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 70 or the amino acid sequence of SEQ ID NO:
- 70 having one conservative amino acid substitution, and an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 83 or the amino acid sequence of SEQ ID NO:
- 83 having one conservative amino acid substitution.
An isolated monoclonal anti-Siglec-7 antibody, wherein the anti-Siglec-7 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 299-308 and 487-489.
An isolated monoclonal anti-Siglec-7 antibody, wherein the anti-Siglec-7 antibody comprises a light chain variable domain and a heavy chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 429-438 and 493-496.
Dependencies are inferred from the claim text.